Table 1.
Patient demographics and characteristics.
| Spanish aCGH | DFCI MIP | |||
|---|---|---|---|---|
| N | % | N | % | |
| 94 | 100% | 34 | 100% | |
| Pathological stage* | ||||
| Stage 0 (Ta) | 10 | 11% | 0 | 0% |
| Stage I (T1) | 5 | 5% | 1 | 3% |
| Stage II (T2) | 45 | 48% | 1 | 3% |
| Stage III (T3, T4) | 28 | 30% | 13 | 38% |
| Stage IV (L, M) | 5 | 5% | 10 | 29% |
| Missing | 1 | 1% | 9 | 26% |
| Metastatic sites | ||||
| Local | 16 | 17% | 9 | 26% |
| Bone | 13 | 14% | 5 | 15% |
| Liver | 8 | 9% | 9 | 26% |
| Lymph nodes | 36 | 38% | 13 | 38% |
| Lung | 7 | 7% | 13 | 38% |
| Others | 9 | 10% | 9 | 26% |
| Unknown | 5 | 5% | 0 | 0% |
| Visceral disease | ||||
| Yes | 34 | 36% | 19 | 56% |
| No | 60 | 64% | 15 | 44% |
| Unknown | ||||
| ECOG performance status | ||||
| 0 | 34 | 36% | 15 | 44% |
| > 0 | 60 | 63% | 17 | 50% |
| Unknown | 2 | 6% | ||
| Survival | ||||
| Died | 46 | 49% | 29 | 85% |
| Alive | 48 | 51% | 4 | 12% |
| Unknown | 1 | 3% | ||
*
Pathological stage at time of surgery. All patients either presented with metastatic disease or subsequently developed metastatic disease after local therapy.